Maxim Analyst Notes Sellas Shares Up Over 100%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Maxim analyst Jason McCarthy notes that earlier this week, Sellas announced an update on the ongoing Phase 3 REGAL trial evaluating Galipepimut-S in acute myeloid leukemia patients in second complete remission. Sellas reported that its Contract Research Organization informed the company that 72 events - deaths - had occurred as of December 26, 2025, placing the study near the 80-event threshold required to trigger top-line data. In any clinical trial, pinpointing the timing of events and survival timelines is challenging, the firm acknowledges. While top-line was expected by year-end 2025, delays in an event-driven trial like REGAL could be suggestive of extended survival benefit from GPS, though Maxim would preface this view with the rationale that the data is still completely blinded "so we have to wait and see." Shares of Buy-rated Sellas have continued to rally in December, ahead of the data; up over 100% this month, including 15% on the trial update, the firm adds.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLS is 7.25 USD with a low forecast of 7.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.890
Low
7.00
Averages
7.25
High
7.50
Current: 3.890
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SELLAS Life Sciences Expands SLS009 Clinical Study with IMPACT-AML in Europe
- Clinical Study Expansion: SELLAS Life Sciences has signed an agreement with IMPACT-AML to expand the clinical development of SLS009 into Europe, with plans to enroll 40 newly diagnosed AML patients, aiming to accelerate patient enrollment and broaden drug accessibility.
- U.S. Enrollment Plans: The U.S. clinical trial is expected to begin in Q1 2026, with European enrollment anticipated in Q2 2026, demonstrating the company's commitment to advancing SLS009 on a global scale.
- Market Performance Decline: SLS stock has ended in the red in five of the last seven sessions, with the latest trading down 3.2%, as investors booked profits amid dilution concerns, putting pressure on the stock price.
- Investor Sentiment: Despite the stock's decline, retail sentiment on Stocktwits remains bullish, with investors believing that validating SLS009 in both the U.S. and EU simultaneously will attract global buyers like Novartis.
Continue Reading
SELLAS Life Sciences Partners with IMPACT-AML to Advance SLS009 Clinical Trials
- Clinical Trial Expansion: SELLAS Life Sciences has entered into an agreement with IMPACT-AML to recruit approximately 40 newly diagnosed high-risk acute myeloid leukemia (AML) patients in the U.S. by Q1 2026, leveraging existing infrastructure for efficient European patient enrollment.
- Drug Combination Evaluation: SLS009 will be evaluated in combination with azacitidine (AZA) and venetoclax (VEN), aiming to enhance treatment outcomes for newly diagnosed AML patients, which is expected to significantly improve clinical results.
- International Collaboration Network: The IMPACT-AML project connects multiple European clinical institutions, allowing SELLAS to accelerate clinical research in a cost-effective manner, thereby enhancing the market potential of SLS009.
- Strategic Significance: This collaboration not only provides strong external validation for SELLAS but also reflects the potential of SLS009 in addressing critical unmet needs in AML, further solidifying SELLAS's market position in cancer treatment.
Continue Reading